- \n
- QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna\u2122 TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna\u2019s Navicixizumab <\/i><\/li>\n
- Agreements include a non-exclusive license for QIAGEN to the OncXerna Xerna\u2122 TME panel <\/i><\/li>\n
- The agreements broaden QIAGEN\u2019s NGS companion diagnostics capabilities in immuno- oncology clinical development programs<\/i><\/li>\n<\/ul>\n
HILDEN, Germany & WALTHAM, Mass. & GERMANTOWN, Md.–(BUSINESS WIRE<\/a>)–
\nQIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and OncXerna Therapeutics, Inc. (\u201cOncXerna\u201d), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna\u2019s product candidate, Navicixizumab, and a non-exclusive license to the Xerna\u2122 TME panel.\n<\/p>\n\nQIAGEN and OncXerna have agreed to collaborate to advance the Xerna\u2122 TME panel towards IVD (in-vitro diagnostic) regulatory approval as a NGS companion diagnostic for Navicixizumab, which is being developed by OncXerna as a treatment for patients with ovarian cancer. The diagnostic will be used to determine if patients with ovarian cancer whose dominant tumor biology is driven by angiogenesis are more likely to benefit from treatment with Navicixizumab.\n<\/p>\n
\nThe Xerna\u2122 TME panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on the dominant biology of their cancer so that patients can be matched with therapies that directly address these biologies. Pursuant to the non-exclusive license, which is for research use only (\u201cRUO\u201d) and clinical development programs, OncXerna has granted QIAGEN the rights to integrate the Xerna\u2122 TME panel into their NGS workflow solutions, which broadens QIAGEN\u2019s NGS CDx custom panel development capabilities.\n<\/p>\n
\n\u201cWe are very pleased to complete these agreements with QIAGEN, which we see as providing important external validation for the Xerna\u2122 TME panel and our broader RNA-based biomarker platform,\u201d stated Dr. Laura Benjamin, OncXerna Founder and CEO. \u201cAs an NGS industry-leader in precision medicine diagnostics with impressive global development, manufacturing and commercial capabilities, we believe QIAGEN is uniquely positioned to help advance the Xerna\u2122 TME panel towards regulatory approval as an NGS companion diagnostic and, if approved, drive the panel\u2019s adoption. Moreover, integration of the Xerna\u2122 TME Panel into their workflow solutions could enable QIAGEN to provide a new RNA-based offering to strengthen their overall immune oncology solutions for biopharma customers.\u201d\n<\/p>\n
\n\u201cWe believe that the Xerna\u2122 TME panel that we can now offer our customers will further enhance our strong portfolio in companion diagnostics. Through this agreement, we aim to foster additional NGS-based collaborations with pharmaceutical companies for the development of drug treatments for immune oncology and promote early clinical adoption of precision medicine diagnostics such as our therascreen<\/i> portfolio and the Xerna\u2122 TME panel,\u201d said Jonathan Arnold, Vice President, Head of Oncology and Precision Diagnostics at QIAGEN. \u201cWe are also thrilled to have the master CDx agreement in place and look forward to working with OncXerna to develop an NGS companion diagnostic for Navicixizumab based on our extensive track record with the development of companion diagnostics for a variety of cancers.\u201d\n<\/p>\n
\nQIAGEN is a pioneer in Precision Medicine and the global leader in collaborations with pharmaceutical and biotechnology companies to co-develop companion diagnostics, which detect clinically relevant genetic abnormalities to provide insights that guide clinical decision-making in diseases such as cancer. QIAGEN has an unmatched depth and breadth of technologies from next-generation sequencing (NGS) to polymerase chain reaction (PCR) for companion diagnostic development. QIAGEN has ten PCR based companion diagnostic indications that are FDA approved, including therascreen<\/i> EGFR for non-small cell lung cancer, therascreen<\/i> KRAS for colorectal cancer, therascreen<\/i> FGFR for urothelial cancer, therascreen<\/i> PIK3CA for breast cancer based on tissue or plasma samples and the therascreen<\/i> BRAF kit for colorectal cancer.\n<\/p>\n
\nCurrently, QIAGEN is working under master collaboration agreements with more than 25 companies to develop and commercialize companion diagnostic tests for their drug candidates \u2013 a deep pipeline of potential future products to advance Precision Medicine for the benefit of patients.\n<\/p>\n
About OncXerna Therapeutics, its Xerna\u2122 RNA-based Biomarker Platform, and Xerna\u2122 TME Panel <\/b><\/p>\n
\nOncXerna is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates. OncXerna is working to expand next-generation precision medicine to a larger group of cancer patients by leveraging the company\u2019s Xerna\u2122 platform to prospectively identify patients based on the dominant biology of their cancer. OncXerna\u2019s approach pairs those patients with OncXerna\u2019s clinical-stage therapeutic candidates and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes. The Xerna\u2122 TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on the interplay between angiogenic and immunogenic dominant biologies of the tumor microenvironment (TME), and has been developed as a clinical assay. The Xerna\u2122 TME Panel is an investigational assay that has not been approved, and has not been demonstrated to be safe or effective for any use.\n<\/p>\n
About Navicixizumab<\/strong><\/p>\n
\nNavicixizumab is an anti-DLL4\/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin\u00ae (bevacizumab) in a Phase 1b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal, or fallopian tube cancer in patients who have received at least three prior therapies and\/or prior treatment with Avastin\u00ae. Navicixizumab is an investigational agent that has not been approved, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.\n<\/p>\n
About QIAGEN<\/b><\/p>\n
\nQIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2021, QIAGEN employed approximately 5,900 people in over 35 locations worldwide. Further information can be found at http:\/\/www.qiagen.com<\/a><\/p>\n
Forward-Looking Statement<\/b><\/p>\n
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and\/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading \u201cRisk Factors\u201d contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. <\/i><\/p>\n
\nSource: QIAGEN N.V.\n<\/p>\n
\nCategory: Corporate\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210809005763\/en\/<\/a><\/span><\/p>\n
QIAGEN<\/b><\/p>\n
Investor Relations
\n<\/b>
John Gilardi, +49 2103 29 11711
\n
Phoebe Loh, +49 2103 29 11457
\n
e-mail: ir@QIAGEN.com<\/a><\/p>\nPublic Relations
\n<\/b>
Thomas Theuringer, +49 2103 29 11826
\n
Robert Reitze, +49 2103 29 11676
\n
e-mail: pr@QIAGEN.com<\/a><\/p>\n - Agreements include a non-exclusive license for QIAGEN to the OncXerna Xerna\u2122 TME panel <\/i><\/li>\n